<DOC>
	<DOCNO>NCT00512278</DOCNO>
	<brief_summary>The aim study investigate subject receive first course peg-interferon α-2b plus ribavirin therapy chronic HCV infection ( genotype 1 ) whether addition infliximab standard regimen pegylated interferon α-2b combination ribavirin : - increase proportion subject attain sustained virological response SVR ( undetectable blood Hepatitis C viral load 6 month treatment ) - improve safety profile compare regimen without infliximab</brief_summary>
	<brief_title>Infliximab Treatment Along With Pegylated Interferon Ribavirin Treatment Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female subject , &gt; 18 year age proven chronic ( great 6 month ) hepatitis C infection ( genotype 1 ) never treat pegylated interferon α2b /or ribavirin . Criteria inclusion trial follow : Male female , 18 year age older Positive HCV RNA , Genotype 1 , treatment naïve ( never receive pegylated interferon / ribavirin ) Evidence chronic HCV infection least six month prior screen Findings liver biopsy within past 36 month consistent presence chronic hepatitis C infection . Negative hepatitis B surface antigen No evidence hemochromatosis Hemoglobin ≥12 g/dL female ≥13 g/dL male WBC ≥3.0 x 109/L neutrophil ≥1.5 x 109/L Platelets ≥80 x109/L Direct Bilirubin WNL +/ 50 % central laboratory normal range . Total bilirubin ≤1.6 . Albumin within normal limit Serum creatinine within normal limit . Serum thyroid stimulate hormone ( TSH ) level within normal limit Men woman childbearing potential must use two form adequate birth control measure duration study continue precaution 6 month receive last infusion . Subjects history mild depression may consider entry study . No history latent active TB . Women pregnant , nursing , plan pregnancy within 6 month last infusion men partner pregnant baseline intend become pregnant within 6 month last infusion . Known allergy infliximab , ribavirin , pegylated interferon Decompensated liver disease characterize decreased hepatic synthetic functioning abnormal albumin bilirubin level , prolong prothrombin time complication include ascites recent variceal bleed history latent active granulomatous infection , include TB , histoplasmosis , coccidiomycosis ( Valley Fever ) History autoimmune hepatitis history poorly control autoimmune disease Use systemic antiinflammatory medication except NSAIDs low dose systemic steroid Previous treatment monoclonal antibody antibody fragment History receive human/murine recombinant product know allergy murine product Documentation seropositive human immunodeficiency virus ( HIV ) History alcohol substance abuse within precede 6 month , opinion investigator , may increase risk associate study participation study agent administration , may interfere interpretation result History serious infection ( e.g. , hepatitis , pneumonia pyelonephritis ) previous 3 month Opportunistic infection within 6 month prior screen History lymphoproliferative disease Currently know malignancy history malignancy within previous 5 year , exception basal cell squamous cell carcinoma skin fully excise evidence recurrence Current sign symptom severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral disease Treatment therapeutic agent target reduce TNF within 3 month screen Presence transplant solid organ Concomitant diagnosis history congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
</DOC>